Press Releases

SOLCO HEALTHCARE U.S. ANNOUNCES THE APPROVAL OF GENERIC CYMBALTA® CAPSULES IN THE UNITED STATES

Aug 21, 2017 15:10

CRANBURY, NJ – Solco Healthcare U.S. is proud to announce that the U.S. Food and Drug Administration (FDA) approved its generic equivalent of Cymbalta® Capsules (Duloxetine delayed-release capsules), 20mg, 30mg and 60mg.  The product is available now.

Duloxetine is used to treat major depressive disorder in adults. Duloxetine is also used to treat general anxiety disorder in adults and children who are at least 7 years old.  Duloxetine may be used in adults to treat fibromyalgia (a chronic pain disorder), or chronic muscle or joint pain (such as low back pain and osteoarthritis pain).

"We are pleased to receive this FDA approval, which adds to our growing line of central nervous system acting agents. We continue to strengthen our presence within the US generic market by providing high quality medicines at affordable prices,” said Hai Wang, President of Solco Healthcare.

According to QuintilesIMS, U.S. brand and generic sales of Duloxetine delayed-release capsules were approximately $484.4 million for the 12 months ending in June 2017.

Solco News

Here you will find useful healthcare related information and latest industry news, including exclusive content available only on Solco News.


Archives

2017 2016